BRIEF-Catalyst Pharma Submits NDA For Firdapse
March 29, 2018 at 08:21 AM EDT
* CATALYST PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR FIRDAPSE® FOR TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|